liquid crystal mixture comprising one or several compounds of formula (I)
##STR00001##
wherein R1, R2, R3, R4, R5, R6, M1, M2, X, A, and m are defined herein.
|
##STR00121##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—,
and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 is a linear or branched alkyl group of 2 to 20 C atoms, or a linear or branched alkenyl group of 5 to 20 C atoms, wherein in either case one or two —CH2-groups optionally are replaced by —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
or F
or a radical
##STR00122##
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M2 represents a single bond, —OC(═O)—, or —C(═O)O—;
A is
##STR00123##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00124##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3;
m is 1; and
M1 is a single bond.
##STR00053##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) H or F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00054##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M2 represents a single bond, —OC(═O)—, —C(═O)O—, —OCH2—, or —NH—;
A is
a) a linear or branched alkan-α,ω-diyl group of 1 to 20 C atoms or alkene-α,ω-diyl group of 2 to 20 C atoms, optionally, if non-adjacent to M1 and M2, one or two non-adjacent —CH2— groups are replaced by —O—, or
b)
##STR00055##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00056##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3;
m is 0 or 1; and
M1 is a single bond.
##STR00049##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00050##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1, M2 represent, independently from another, a single bond, —OC(═O)—, —C(═O)O—, —OCH2—, or —NH—;
A is
i) —C(═Y)—, wherein Y is CH—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—,
ii) —CHY—, wherein Y is CH2—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—,
iii)
##STR00051##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2—;
##STR00052##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 0 or 1; or
X and M1-(A)m-M2-R2 together are
a) a ring of 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms,
b) a combination of two either directly linked or spiro-linked rings of, independently from another, 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms, wherein the rings, independently from another, are carbocycles or carbocycles comprising B, N, O or S heteroatoms.
##STR00093##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00094##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 represents —OCH2— or —NH—;
M2 represents —OC(═O)—, —C(═O)O— or —NH—;
A is
##STR00095##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2—;
##STR00096##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 0 or 1; or
X and M1-(A)m-M2-R2 together are
a) a ring of 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms,
b) a combination of two either directly linked or spiro-linked rings of, independently from another, 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms, wherein the rings, independently from another, are carbocycles or carbocycles comprising B, N, O or S heteroatoms;
or
##STR00097##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00098##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M2 represents a single bond, or —C(═O)O—;
A is
##STR00099##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00100##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3;
m is 1; and
M1 is a single bond.
##STR00101##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 5 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00102##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 represents —OCH2—, or —NH—, and M2 represents —NH—, and if A denotes —C(═Y)— or —CHY—, then M1 and M2 represent —C(═O)O— and —OC(═O)—, respectively;
A is
##STR00103##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2—;
##STR00104##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 1; or
X and M1-(A)m-M2-R2 together are
a) a ring of 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms,
b) a combination of two either directly linked or spiro-linked rings of, independently from another, 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms, wherein the rings, independently from another, are carbocycles or carbocycles comprising B, N, O or S heteroatoms,
or
##STR00105##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 5 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00106##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 is a single bond;
M2 represents a single bond, —OC(═O)—, or —C(═O)O—;
if A denotes —C(═Y)— or —CHY—, then M1 and M2 represent —C(═O)O— and —OC(═O)—, respectively;
A is
i) —C(═Y)—, wherein Y is CH—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—, respectively,
ii) —CHY—, wherein Y is CH2—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—, respectively,
iii)
##STR00107##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00108##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 1.
##STR00077##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a radical
##STR00078##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 represents a single bond, —OCH2—, or —NH—;
M2 represents —C(═O)O—;
A is
##STR00079##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2—;
##STR00080##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 1; or
X and M1-(A)m-M2-R2 together are
a) a ring of 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms,
b) a combination of two either directly linked or spiro-linked rings of, independently from another, 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms, wherein the rings, independently from another, are carbocycles or carbocycles comprising B, N, O or S heteroatoms;
##STR00081##
wherein
R1 is H or alkyl of 1 to 12 C atoms;
R2 is H, a linear or branched alkyl group of 1 to 16 C atoms, or linear or branched alkenyl group of 2 to 16 C atoms, wherein in either case one —CH2— group is optionally replaced by —O—, and optionally one or more H are replaced by F;
M1 is —OC(═O)— or a single bond;
M3 is a single bond;
G1-G2 is —CH2—CH— or —CH═C—;
p is 0 or 1;
##STR00082##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl;
##STR00083##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, or cyclohexylen-1,4-diyl,
with the provisos that
a) R2 is H only in case p is 1;
b) if p is 0, then R2 is a linear or branched alkyl group of 1 to 16 C atoms or linear or branched alkenyl group of 2 to 16 C atoms and
##STR00084##
is cyclohexylen-1,4-diyl; and
c) -G1-G2- can be —CH═C— only in the case M1 is a single bond;
##STR00085##
wherein
R1 is H or alkyl of 1 to 12 C atoms;
R2 is H, a linear or branched alkyl group of 1 to 16 C atoms, or linear or branched alkenyl group of 2 to 16 C atoms, wherein in either case one —CH2— group is optionally replaced by —O—, and optionally one or more H are replaced by F;
M1 is —OC(═O)— or a single bond;
M3 is a single bond;
G1-G2 is —CH2—CH— or —CH═C—;
p is 0 or 1;
##STR00086##
is pyrimidin-2,5-diyl, pyridin-2,5-diyl, which is optionally ortho to N substituted by F, phenylen-1,4-diyl, which is optionally substituted by one or two F, or cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl;
##STR00087##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl, pyrimidin-2,5-diyl, or pyridin-2,5-diyl, which is optionally ortho to N substituted by F,
with the provisos that
a) one and only one of
##STR00088##
is pyrimidin-2,5-diyl or pyridine-2,5-diyl, which is optionally ortho to N substituted by F; and
b) -G1-G2 can be —CH═C— only in case M1 is a single bond;
##STR00089##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a radical
##STR00090##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M2 represents a single bond, —OC(═O)—, or —C(═O)O—;
A is
##STR00091##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00092##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3;
m is 1; and
M1 is a single bond.
2. A liquid crystal mixture according to
5. A liquid crystal mixture according to
9. A liquid crystal display device according to
10. A liquid crystal display device according to
11. A liquid crystal display device according to
##STR00057##
wherein
X is H;
R1 is H or alkyl of 1 to 4 C atoms; and
R3, R4, R5, R6 are CH3.
##STR00058##
wherein
X is H;
R1 is H or alkyl of 1 to 4 C atoms; and
R3, R4, R5, R6 are CH3.
##STR00059##
wherein
X is H;
R1 is H or alkyl of 1 to 4 C atoms; and
R3, R4, R5, R6 are CH3.
##STR00060##
wherein
X is H;
R1 is H or alkyl of 1 to 4 C atoms;
R3, R4, R5, R6 are CH3;
R2 is H or an alkyl or alkoxy group of 1 to 16 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —OC(═O)— or —Si(CH3)2—, and optionally one or more H is replaced by F or CH3;
M1 is —OC(═O)—;
M2 is a single bond; and
##STR00061##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, or is cyclohexylen-1,4-diyl, or pyrimidine-2,5-diyl, or pyridine-2,5-diyl.
##STR00062##
wherein
X is H;
R1 is H or alkyl of 1 to 4 C atoms;
R3, R4, R5, R6 are CH3;
R2 is H or an alkyl or alkoxy group of 1 to 16 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —OC(═O)— or —Si(CH3)2—, and optionally one or more H is replaced by F or CH3;
M1 is —OC(═O)—;
M2 is a single bond;
M3 is a single bond, —OC(═O)—, or —OCH2—;
##STR00063##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, or is cyclohexylen-1,4-diyl, pyrimidine-2,5-diyl, or pyridine-2,5-diyl; and
##STR00064##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, or is cyclohexylen-1,4-diyl, pyrimidine-2,5-diyl, or pyridine-2,5-diyl.
##STR00065##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) H or F,
b) a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
c) a radical
##STR00066##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M2 represents a single bond, —OC(═O)—, —C(═O)O—, —OCH2—, or —NH—;
A is
a) a linear or branched alkan-α,ω-diyl group of 1 to 20 C atoms or alkene-α,ω-diyl group of 2 to 20 C atoms, optionally, if non-adjacent to M1 and M2, one or two non-adjacent —CH2— groups are replaced by —O—, or
b)
##STR00067##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00068##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3;
m is 0 or 1; and
M1 is a single bond.
##STR00069##
wherein
R1 is H or alkyl of 1 to 12 C atoms;
R2 is H, a linear or branched alkyl group of 1 to 16 C atoms, or linear or branched alkenyl group of 2 to 16 C atoms, wherein in either case one —CH2— group is optionally replaced by —O—, and optionally one or more H are replaced by F;
M1 is —OC(═O)— or a single bond;
M3 is a single bond;
G1-G2 is —CH2—CH— or —CH═C—;
p is 0 or 1;
##STR00070##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl;
##STR00071##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, or cyclohexylen-1,4-diyl,
with the provisos that
a) R2 is H only in case p is 1;
b) if p is 0, than R2 is a linear or branched alkyl group of 1 to 16 C atoms or linear or branched alkenyl group of 2 to 16 C atoms and
##STR00072##
is cyclohexylen-1,4-diyl; and
c) -G1-G2- can be —CH═C— only in the case M1 is a single bond.
##STR00073##
wherein
R1 is H or alkyl of 1 to 12 C atoms;
R2 is H, a linear or branched alkyl group of 1 to 16 C atoms, or linear or branched alkenyl group of 2 to 16 C atoms, wherein in either case one —CH2— group is optionally replaced by —O—, and optionally one or more H are replaced by F;
M1 is —OC(═O)— or a single bond;
M3 is a single bond;
G1-G2 is —CH2—CH— or —CH═C—;
p is 0 or 1;
##STR00074##
is pyrimidin-2,5-diyl, pyridin-2,5-diyl, which is optionally ortho to N substituted by F, phenylen-1,4-diyl, which is optionally substituted by one or two F, or cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl;
##STR00075##
is phenylen-1,4-diyl, which is optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, which is optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, wherein the phenyl moiety is optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl, pyrimidin-2,5-diyl, or pyridin-2,5-diyl, which is optionally ortho to N substituted by F,
with the provisos that
a) one and only one of
##STR00076##
is pyrimidin-2,5-diyl or pyridine-2,5-diyl, which is optionally ortho to N substituted by F; and
b) -G1-G2 can be —CH═C— only in case M1 is a single bond.
##STR00109##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F
b) a linear or branched alkyl group of 1 to 20 C atoms, wherein one or two —CH2— groups optionally are replaced by —Si(CH3)2—, and/or one or more H of the alkyl group is replaced by F or CH3,
c) a radical
##STR00110##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 represents —OCH2—, or —NH—, and M2 represents —NH—, and if A denotes —C(═Y)— or —CHY—, then M1 and M2 represent —C(═O)O— and —OC(═O)—, respectively;
A is
##STR00111##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2—;
##STR00112##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 1; or
X and M1-(A)m-M2-R2 together are
a) a ring of 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms,
b) a combination of two either directly linked or spiro-linked rings of, independently from another, 4 to 16 members, optionally substituted by an alkyl radical of 1 to 15 C atoms, wherein the rings, independently from another, are carbocycles or carbocycles comprising B, N, O or S heteroatoms,
or
##STR00113##
wherein
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2-groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R2 stands for
a) F,
b) a linear or branched alkyl group of 1 to 20 C atoms, wherein one or two —CH2— groups optionally are replaced by —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl group is replaced by F or CH3,
c) a radical
##STR00114##
wherein independently from the respective meanings in (I)
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms;
M1 is a single bond;
M2 represents a single bond, —OC(═O)—, or —C(═O)O—;
if A denotes —C(═Y)— or —CHY—, then M1 and M2 represent —C(═O)O— and —OC(═O)—, respectively;
A is
i) —C(═Y)—, wherein Y is CH—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—, respectively,
ii) —CHY—, wherein Y is CH2—Z, wherein Z is phenylen-1,4-diyl, optionally substituted by one to three halogen atoms, alkyl or alkyloxy groups of 1 to 4 C atoms, with the proviso that M1 and M2 are —C(═O)O— and —OC(═O)—, respectively,
iii)
##STR00115##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2;
##STR00116##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl;
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3; and
m is 1.
26. A compound of
R1 is a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one —CH2— group is replaced by cyclohexylen-1,4-diyl,
and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3.
##STR00117##
wherein independently from the respective meanings in (I)
R1 is H or a linear or branched alkyl group of 1 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case optionally one —CH2— group is replaced by cyclohexylen-1,4-diyl, or one or two —CH2— groups optionally are replaced by —O—, if non-adjacent to N, or by —C(═O)—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group optionally is replaced by F or CH3;
R3, R4, R5, R6 are, independently from another, an alkyl group of 1 to 8 C atoms; and
X is H, OH, a linear or branched alkyl or alkyloxy group of 1 to 20 C atoms, wherein one or two —CH2— groups are optionally replaced by —O—, —C(═O)O—, or —Si(CH3)2—, and optionally one or more H are replaced by F or CH3.
##STR00118##
wherein
p and q are 0, 1 or 2, wherein the sum of p+q is 1;
M3 is a single bond or —OC(═O)—, —C(═O)O—, —OCH2—, —CH2O—, —C≡C—, —CH2CH2—, or —CH2CH2CH2CH2; and
##STR00119##
are, independently from another, phenylen-1,4-diyl, which is optionally substituted by one, two or three F, or cyclohexan-1,4-diyl, which is optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, which is optionally substituted by one F, pyridine-2,5-diyl, which is optionally substituted by one F, or naphthalene-2,6-diyl, which is optionally substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl, wherein the aromatic ring is optionally substituted by one, two or three F, or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol,2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl.
29. A compound of
R2 is a linear or branched alkyl group of 2 to 20 C atoms, or a linear or branched alkenyl group of 2 to 20 C atoms, wherein in either case one or two —CH2— groups optionally are replaced by —C(═O)O—, or —Si(CH3)2—, and/or one or more H of the alkyl or alkenyl group is replaced by F or CH3,
or F
or a radical
##STR00120##
|
|||||||||||||||||||||||||||||||||||||||||
This application is a continuation application of Ser. No. 10/363,009, filed Feb. 26, 2003, the contents of which are hereby incorporated herein by reference; which is the National Stage of International Application No. PCT/EP01/09832, filed Aug. 25, 2001, the contents of which are hereby incorporated herein by reference; which claims priority to European Patent Application No. 00118736.8, filed Aug. 30, 2000, the contents of which are hereby incorporated herein by reference.
The present invention relates to a novel liquid crystal mixture. More particularly, it relates to a chiral smectic or ferroelectric liquid crystal mixture, which is chemically very stable against heat and light, thus being especially suitable for active matrix panels. A further aspect of this invention is the use of this liquid crystal mixture in displays, especially active matrix displays. Yet another aspect of this invention are active matrix displays comprising such a mixture.
Since Clark and Lagerwall found Surface Stabilized Ferroelectric Liquid Crystals (SSFLC) in 1980 [N. A. Clark and S. T. Lagerwall, Appl. Phys. Lett., 36, 899 (1980)], these liquid crystals have attracted attentions as display materials in the coming generation and a number of studies have been carried out thereon.
There are two major advantages of FLC displays: the ‘pixel speed’ is easily 100 or even 1000 times faster than nematics and secondly, due to the bistability, the resolution of such displays is not limited by the material.
However, passive matrix FLC displays are limited by certain trade-off relationships: the higher the number of scanning lines, the higher is the frame addressing time and thus the speed of a display is always in competition with its resolution.
With respect to the trade-offs of passive matrix FLC displays several authors have suggested to combine the active matrix with FLC. The first approach was made by Hartmann (IEEE Trans. Electron. Devices 1989, 36(9), part 1, pp. 1895-9) in the 80s utilising the charge-controlled bistability of a quasi-bookshelf FLC with MOS-FET technology. The large Ps values, however, prohibited higher resolution with a-Si TFT driving.
Takatoh et. al. (6th International Conference on Ferroelectric Liquid Crystals, 1997, 20-24 Jul., Brest, France; M. Takatoh et al. 1998, SID Digest, 1171-1174) have demonstrated an AM display based upon chiral smectics using a very high PS material driven with an active matrix with polycrystalline Silicon-TFT. Nito et. al. (Nito et al., 1993, Journal of the SID, 1/2, 163-169) have suggested a monostable AM-FLC with much lower PS, however, with the disadvantage of a stripey FLC texture which is not suitable for high contrast displays without further improvements. Furue et. al. (Furue, H. et al., 1998, IDW '98, 209-212) suggested a polymer stabilized SSFLCD with a FELIX® mixture with a material having a moderate PS value.
High PS-values require long charge-up times on each of the pixels and are therefore incompatible with high resolution, i.e. a large number of scanning lines. This is the reason why Takatoh et. al. have used a special poly-crystalline silicon active matrix that allows for higher current densities as compared to the standard and cost-effective amorphous silicon TFT.
Asao et. al. have presented a monostable FLC mode (Y. Asao et al., ILCC 2000, Sendai, and Jpn. J. Appl. Phys. 38, L534-L536, 1999 therein called “half-V-shape FLC” mode; see also T. Nonaka et. al., Liquid Crystals 26(11), 1599-1602, 1999, therein called “CDR” mode). Such displays provide, by virtue of their smaller PS values, solutions for the gray scale problem and the resolution limitation caused by too large PS values in active matrix panels.
A remaining problem in the application of TFT-LCD (e.g. monostable FLC) is the limited “holding ratio”, caused by the activity of the manifold of charge carriers that are present in the pixel volume and which tend to discharge the pixel within too short a time. In particular for the fast switching displays with a very thin cell gap the problem of ionic charges which build up depolarisation fields leads to significant limitations (cp. Sasaki, Japan Display 1986, 62; Nakazono, Int. Dev. Res. Cent. Techn. Rep. IDRC 1997, 65; Naemura, SID Dig. Techn. Pap. 1989, 242; Fukuoka, AM LCD 1994, 216; Takatori, AM-LCD 97 DIGEST 1997, 53; Takatoh, Polym. Adv, Technol. 11, 413 (2000)).
Thus it is an important factor to maintain a very low ion content and to achieve chemical stability against heat and light, both of which could cause additional ion formation. This demand has in practice lead to the exclusion of any material comprising hetero atoms such as N, S, even O in liquid crystal mixtures for active matrix (i.e. TFT or MIM) applications {cp. e.g. Petrov et al., Liq. Cryst. 19(6), 729 (1995) [CAN 124:101494]; Petrov, Proc. SPIE-Int. Soc. Opt. Eng. (1995), 2408 [CAN 123:241500]; Dabrowski, Biul. Wojsk. Akad. Techn. 48(4), 5 (1999) [CAN 131:163227]; Kirsch, Angew. Chem., Int. Ed. 39(23), 4216 (2000) and references cited in these papers}. Whereas, so far, this could successfully be done for nematics (cp. e.g. DE-A 1 962 9812, p. 12 to 16), there is hardly any smectic (Sc) material without such hetero atoms (cp. Demus et al., Flüssige Kristalle in Tabellen, vol. 1 and 2). Thus the use of fast switching smectics for TFT application is strongly limited if not prohibited and the range of potentially available nematics is strongly reduced.
The object of the present invention was therefore to provide a liquid crystal mixture with very high resistivity or holding ratio irrespective of the comprisment of hetero atoms, especially a chiral smectic, in particular ferroelectric or antiferroelectric liquid crystal mixtures which are suitable for active matrix panels, especially with respect to withstanding heat- or light-induced chemical stress while maintaining the performance of a low-ion-content mixture.
The present invention provides a liquid crystal mixture, especially a chiral smectic mixture, in particular a ferroelectric or antiferroelectric liquid crystal mixture, most particularly a monostable ferroelectric liquid crystal mixture comprising one or several compounds of formula (I)
##STR00002##
wherein
##STR00003##
wherein independently from the respective meanings in (I)
##STR00004##
wherein
##STR00005##
are independently from another phenylen-1,4-diyl, which optionally can be substituted by one, two or three F, or cyclohexan-1,4-diyl, which can optionally be substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, optionally substituted by one F, pyridine-2,5-diyl, which can optionally be substituted by one F, or naphthalene-2,6-diyl, which can optionally be substituted by one, two or three F, or 1,2,3,4-tetrahydronaphthalene-2,6-diyl (the aromatic ring optionally substituted by one, two or three F), or decahydronaphthalene-2,6-diyl, or indane-2,5(6)-diyl, or fluorene-2,-7-diyl, or phenanthrene-2,7-diyl, or 9,10-dihydrophenanthrene-2,7-diyl, or (1,3,4)thiadiazol-2,5-diyl, or (1,3)thiazol-2,5-diyl, or (1,3)thiazol-2,4-diyl, or thiophen-2,4-diyl, or thiophen-2,5-diyl, or (1,3)dioxan-2,5-diyl, or piperidin-1,4-diyl, or piperazin-1,4-diyl
Especially preferred are mixtures comprise 0.1 wt.-% to 5 wt.-% of one or several compounds of formula (I).
Preferably the mixtures comprise one or several compounds of the following formulae
##STR00006##
wherein
##STR00007##
wherein
##STR00008##
wherein
##STR00009##
wherein
Particularly preferred are mixtures comprising
##STR00010##
wherein
##STR00011##
wherein
##STR00012##
wherein
##STR00013##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl, pyrimidine-2,5-diyl, pyridine-2,5-diyl
and/or
##STR00014##
wherein
##STR00015##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl, pyrimidine-2,5-diyl, or pyridine-2,5-diyl
##STR00016##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl, pyrimidine-2,5-diyl, or pyridine-2,5-diyl
and/or
##STR00017##
wherein
##STR00018##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl,
and/or
##STR00019##
wherein
##STR00020##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl,
##STR00021##
Several compounds of the formula (I) are commercially available. The synthesis of the not commercially available compounds of formulae (I) and (II), resp., or new compounds of formulae (I), (II), (III) and (IV), resp., are performed in analogy to pertinent papers, e.g. Dagonneau et al., Synthesis 1984, pp. 895-916 [CAN 103:37294]; Rozantsev et al., ACS Symp. Ser. (1985), 280 (Polym. Stab. Degrad), pp. 11-35 [CAN 103:142668].
In particular the commercially available 2,2,6,6-tetramethylpiperidine-4-one and 4-hydroxy-2,2,6,6-tetramethylpiperidine can serve as precursors for the new compounds of formulae (I), (II), (III) and (IV).
E.g. (Ia), wherein M1 and M2 are single bonds, R2 an alkyl group of 1 to 20 C atoms, can be obtained by reacting 2,2,6,6-tetramethyl-4-piperidone with an alkyl magnesium halide to render 4-alkyl-4-hydroxy-2,2,6,6-tetramethyl-piperidine (in analogy to Skowronski et al., Pol. J. Chem. 54, 195, 1980)), dehydration to 3,4-dehydro-4-alkyl-2,2,6,6-tetramethylpiperidine [corresponds to formula (IV)] and consecutive hydrogenation (e.g. in analogy to DE-A 2258086). Alternatively Wittig reagents can be applied for the first step (e.g. in analogy to Collum et al., J. Am. Chem. Soc. 113, 9575 (1991)).
E.g. (Ia), wherein M1 is —OC(═O)—, can be obtained by subjecting 4-hydroxy-2,2,6,6-tetramethylpiperidine to esterification (in analogy to U.S. Pat. No. 4,038,280, Example 14) with an appropriate carboxylic acid derivative X—C(═O)(CH2)-M2-R2 (X: Cl, Br or OH).
E.g. (Ia1), wherein M1 is —OC(═O)— and M2 is —C(═O)O—, can be obtained by subjecting 4-hydroxy-2,2,6,6-tetramethylpiperidine to esterification (in analogy to U.S. Pat. No. 4,038,280, Example 14) with an appropriate carboxylic acid derivative X—C(═O)(CH2)C(═O)X (X: Cl, Br or OH).
E.g. (Ib), wherein M1 is a single bond, M2 is —OCH2—, R an alkyl group of 1 to 20 C atoms and
##STR00022##
is phenylen-1,4-diyl, can be obtained by bringing into reaction 2,2,6,6-tetramethyl-piperidine-4-one and phenol (in analogy to SU 631 516; CA 90:54839) to render 3,4-dehydro-4-(4-hydroxyphenyl)-2,2,6,6-tetramethyl-piperidine, which is hydrogenated to 4-(4-hydroxyphenyl)-2,2,6,6-tetramethyl-piperidine (in analogy to DE-A-2 258 086). This material can be (in analogy to U.S. Pat. No. 4,038,280, Example 25) transferred to the above mentioned examples of (Ib) by reacting with an appropriate alkyl halide X—R2 (X: Halide, Tosylate, Mesylate; R2 not H or F).
E.g. (Ib), wherein M1 is a single bond, M2 is —OC(═O)—, R2 an alkyl group of 1 to 20 C atoms and
##STR00023##
is phenylen-1,4-diyl, can be obtained from above mentioned 4-(4-hydroxyphenyl)-2,2,6,6-tetramethyl-piperidine by esterification with an appropriate carboxylic acid derivative X—C(═O)—R2 (X: Cl, Br, OH; R not H or F) (e.g. in analogy to U.S. Pat. No. 4,038,280, Example 14).
E.g. (Ib), wherein M1 is a single bond, M2 is —OC(═O)— or —OCH2—, R2 an alkyl group of 1 to 20 C atoms and
##STR00024##
is cyclohexyl-1,4-diyl, can be obtained from above mentioned 4-(4-hydroxyphenyl)-2,2,6,6-tetramethyl-piperidine by hydrogenation (in analogy to DE-A-2 415 818) to 4-(4-hydroxycyclohexyl)-2,2,6,6-tetramethyl-piperidine and consecutive etherification with an appropriate alkyl halide X—R2 (X: Halide, Tosylate, Mesylate; R2 not H or F) or esterification with an appropriate carboxylic acid derivative X—C(═O)—R2 (X: Cl, Br, OH; R2 not H or F) (e.g. in analogy to U.S. Pat. No. 4,038,280, Example 14 and 25), resp.
E.g. (Ic), wherein M1 is a single bond, M3 is —OC(═O)—, R2H, F or an alkyl group of 1 to 20 C atoms,
##STR00025##
is phenylen-1,4-diyl or cyclohexyl-1,4-diyl and
##STR00026##
is phenylen-1,4-diyl, optionally substituted by one, two or three F, or cyclohexyl-1,4-diyl, optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, pyridin-2,5-diyl, naphthalin-2,6-diyl, optionally substituted by one, two or three F, thiophen-2,4-diyl, thiophen-2,5-diyl, can be obtained by subjecting above mentioned 4-(4-hydroxy-phenyl)-2,2,6,6-tetramethyl-piperidine and 4-(4-hydroxycyclohexyl)-2,2,6,6-tetramethyl-piperidine, respectively, to esterification with a moiety (X: F, Cl, Br or OH) (e.g. in analogy to U.S. Pat. No. 4,038,280, Example 14).
##STR00027##
E.g. (Ic), wherein M1 is a single bond, M3 is —OCH2—,
##STR00028##
is phenylen-1,4-diyl or cyclohexyl-1,4-diyl and
##STR00029##
is phenylen-1,4-diyl, optionally substituted by one, two or three F, or cyclohexyl-1,4-diyl, optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, pyridin-2,5-diyl, naphthalin-2,6-diyl, optionally substituted by one, two or three F, or thiophen-2,4-diyl, thiophen-2,5-diyl, can be obtained by subjecting (in analogy to U.S. Pat. No. 4,038,280, Example 25) above mentioned 4-(4-hydroxyphenyl)-2,2,6,6-tetramethyl-piperidine and 4-(4-hydroxycyclohexyl)-2,2,6,6-tetramethyl-piperidine, respectively, to etherification with a moiety (X: Cl, Br, Tosylate, Mesylate)
##STR00030##
E.g. (Ic), wherein M1 is a single bond, M3 is a single bond, R2H, F or an alkyl group of 1 to 20 C atoms,
##STR00031##
is phenylen-1,4-diyl or cyclohexyl-1,4-diyl and
##STR00032##
is phenylen-1,4-diyl, optionally substituted by one, two or three F, or cyclohexyl-1,4-diyl, optionally substituted by one CN, CH3 or F, or pyrimidin-2,5-diyl, pyridin-2,5-diyl, naphthalin-2,6-diyl, optionally substituted by one, two or three F, thiophen-2,4-diyl, thiophen-2,5-diyl, can be obtained by subjecting above mentioned 4-(4-hydroxy-phenyl)-2,2,6,6-tetramethyl-piperidine and 4-(4-hydroxycyclohexyl)-2,2,6,6-tetramethyl-piperidine, respectively, after transformation into an appropriate derivate (e.g. triflate), to an aryl-(cyclohexyl-)-aryl coupling reaction {Poetsch, Kontakte (Darmstadt), 1988 (2), p. 15)} with a moiety (X: ClMg—, BrMg—, IMg—, Li—, ClZn—, (HO)2B—).
##STR00033##
E.g. (Id) can be obtained in analogy to (Ic), in all the variants given above.
A further object of the invention is to provide compounds of formula (II) and a nematic liquid crystal mixture comprising at least one compound of formula (I) or (II). Preferably the mixture comprises 0.05 to 5% of one or several compounds of formula (I) and/or (II). Especially preferred are mixtures comprising 0.05 to 5% of one or several compounds of formula (II).
##STR00034##
wherein
##STR00035##
is phenylen-1,4-diyl, optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, optionally substituted by one or two F per ring, 1,1′-cyclohexyl-phenyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl
##STR00036##
is phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl,
with the proviso
##STR00037##
is cyclohexylen-1,4-diyl
A further object of the invention is to provide compounds of formula (III) and a chiral smectic liquid crystal mixture comprising at least one compound of formula (III). Preferably the mixture comprises 0.05 to 5% of one or several compounds of formula (III).
##STR00038##
wherein
##STR00039##
is pyrimidin-2,5-diyl, pyridin-2,5-diyl, optionally ortho to N substituted by F, phenylen-1,4-diyl, optionally substituted by one or two F, or cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl
##STR00040##
is phenylen-1,4-diyl, optionally substituted by one or two F, cyclohexylen-1,4-diyl, biphenyl-4,4′-diyl, optionally substituted by one or two F per ring, 1,1′-cyclohexylphenyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-phenylcyclohexyl-4,4′-diyl, the phenyl moiety optionally substituted by one or two F, or 1,1′-bicyclohexyl-4,4′-diyl, pyrimidin-2,5-diyl, or pyridin-2,5-diyl, optionally ortho to N substituted by F,
with the provisos
##STR00041##
or is pyrimidin-2,5-diyl or pyridin-2,5-diyl, optionally ortho to N substituted by F
Yet another object of the invention is to provide a liquid crystal mixture comprising at least 1 compound of formula (IV)
##STR00042##
wherein R1 to R6, A, M2 and m have the meanings as in formula (I) and M1 is a single bond.
A further object of the invention is to provide a liquid crystal display device, especially one operated in an active matrix panel using the above described mixtures.
A further object of the invention is to provide a chiral smectic liquid crystal display device, especially one operated in an active matrix panel using the above described mixtures.
A further object of the invention is to provide a ferroelectric liquid crystal display device, especially one operated in an active matrix panel using the above described mixtures. With preference this display is a monostable ferroelectric display, such as half-V-shape, CDR or short pitch FLC displays.
A further object of the invention is to provide an antiferroelectric liquid crystal display device, especially one operated in an active matrix panel using the above described mixtures. With preference this display is a monostable antiferroelectric display, such as the so-called “V-shape” mode.
A further object of the invention is to provide a nematic liquid crystal display device, especially one operated in an active matrix panel using the above described mixtures.
Yet a further object of the invention is the use of the above described mixtures in a liquid crystal display, especially one operated in an active matrix panel, especially if the liquid crystal is a chiral smectic, particularly a monostable chiral smectic mode.
The liquid crystal mixtures according to the invention are prepared in a manner which is customary per se. As a rule the components are dissolved in one another, advantageously at elevated temperatures.
The liquid crystal mixtures according to the invention generally comprises of at least two (2), preferably at least five (5), particularly at least eight (8) compounds.
Reference is made to e.g. DE-A-1 985 7352 or DE-A 1 962 9812 (p. 12 to 16) for the LC compounds that can be, besides the compounds of formula (I), (II), (III) or (IV), the constituents of mixtures according to the invention.
Optional additional constituents of the mixtures according to invention are materials that increase the light stability (UV stabilizers, e.g. of the “benzophenone” or “benzotriazole” type). Preferably the mixtures may comprise 0.01 wt.-% to 10 wt.-% of one or several UV stabilizers; especially preferred are mixtures containing 0.1 wt.-% to 5 wt.-% of one or several UV stabilizers.
Optional additional constituents of the mixtures according to invention are materials that increase the stability against oxidative degradation (antioxidants, e.g. of the “sterically hindered phenol” type). Preferably the mixtures may comprise 0.01 wt.-% to 10 wt.-% of one or several antioxidants; especially preferred are mixtures comprise 0.1 wt.-% to 5 wt.-% of one or several antioxidants.
Optionally the mixtures according to invention may comprise a combination of UV stabilizers and antioxidants.
The mixtures according to the invention can be used in electro-optical or fully optical elements, for example display elements, switching elements, light modulators, shutters, elements for image processing and/or signal processing or generally in the area of nonlinear optics.
Chiral smectic liquid crystal mixtures according to the invention are particularly suitable for use in electro-optical switching and display devices (displays). These displays are usually constructed in such a way that a liquid crystal layer is enclosed on both sides by layers which are usually, in this sequence starting from the LC layer, at least one alignment layer, electrodes and a limiting sheet (for example of glass). In addition, they contain spacers, adhesive frames, polarizers and, for color displays, thin color-filter layers or are operated in the sequential backlight technique. Other possible components are antireflection, passivation, compensation and barrier layers and, for active-matrix displays, electric non-linear elements, such as thin-film transistors (TFTs) and metal-insulator-metal (MIM) elements. The structure of liquid crystal displays has already been described in detail in relevant monographs (see, for example, T. Tsukuda, “TFT/LCD Liquid crystal displays addressed by thin film transistors”, Japanese Technology Reviews, 1996 Gordon and Breach, ISBN 2-919875-01-91.
The present invention further provides a chiral smectic liquid crystal (FLC) display device comprising the above-mentioned liquid crystal mixture of the present invention between a pair of substrates each comprising an electrode and an alignment layer formed thereon.
In a preferred embodiment the FLC display is operated in the monostable mode with active matrix panel.
The present invention further provides a nematic liquid crystal display device comprising the above-mentioned liquid crystal mixture of the present invention between a pair of substrates each comprising an electrode and an alignment layer formed thereon. In a preferred embodiment the display is operated in the ECB mode (EP-A 0474062). IPS mode (Kiefer et al., Japan Display '92, S.547) or VA mode (Ohmura et al., SID 97 Digest, S.845).
Several documents are cited in this application, e.g. to discuss the state of the art, synthesis of compounds used in the present invention or application of the mixtures according to the invention. All these documents are hereby incorporated by reference.
A solution of LQT 120 (Hitachi Kasei) is applied onto glass substrates with ITO by spin coating at 2500 rpm. The substrates are heated at 200° C. for 1 hour to form a film. After rubbing the coated film with a nylon cloth in one direction, the substrates are assembled into a cell with spacers having a thickness of 2.0 μm inserted between the substrates in such a manner that the rubbing directions are anti-parallel to each other. The properties of the liquid crystal mixture are measured by filling the liquid crystal mixture into the cell in the isotropic phase, cooling progressively through the nematic, (smectic A phase in case the liquid crystal mixture has one) and the smectic C phase and then applying a rectangular wave pulse (60 Hz) with varying applied voltage (0 to 10V) to the cell at 25° C.
Resistivity and ion-induced spontaneous polarization are measured by means of a MTR-1 device (Toya Technica).
Table 1 summarizes the results thus obtained by adding small quantities of several types of (I) to Sc mixture A and B, respectively. As can be seen by comparing with the respective reference examples rA/rB {comprising no (I)}, the mixtures according to invention surprisingly exhibit a higher resisitivity and decreased ion content. Hence the mixtures according to invention can find application in active-matrix devices.
TABLE 1
Mixture A
Mixture B
Resis-
Resis-
wt.-
tivity
Ion Cont.
wt.-
tivity
Ion Cont.
ex.
%
[TΩcm]
[nC/cm2]
%
[TΩcm]
[nC/cm2]
rA/rB
Without (I)
Trade Name
0
8.5
0.44
0
7.1
2.3
1A 1B
##STR00043##
Sanduvor 3052 Liq.
0.1
>10
<0.1
0.1
7.22
0.24
2A 2B
##STR00044##
Hostavin N20 (Sanduvor 3051 PDR)
0.1
>10
<0.1
0.1
>10
0.25
3A 3B
##STR00045##
VP Sanduvor PR-31
0.1
>10
<0.1
0.1
3
0.24
4A 4B
##STR00046##
TINUVIN 765
1.0
>10
<0.1
1.0
8.4
0.15
5A 5B
##STR00047##
TINUVIN 770
1.0
>10
<0.1
1.0
8.2
0.18
6A
with n = 13 to 16
LICOVIN 845
0.1
>10
<0.1
0.1
8.0
<0.1
6B
##STR00048##
2,2,6,6-Tetramethyl-piperidine-4-(4-octyloxy)benzoate was obtained by esterifying 4-hydroxy-2,2,6,6-tetramethyl-piperidine with 4-octyloxybenzoyl chloride in analogy to U.S. Pat. No. 4,038,280; m.p. 79-81° C.
2,2,6,6-Tetramethyl-piperidine-4-(4′-octyl-biphenyl-4-yl)carboxylate) was obtained in analogy to example 7 from 4′-octyl-biphenyl-4-yl carboxylic acid chloride; m.p. 104-106° C.
2,2,6,6-Tetramethyl-piperidine-4-(trans-4-pentylcyclohexyl)carboxylate was obtained in analogy to example 7 from trans-4-pentylcyclohexyl)carboxylic acid chloride; viscous liquid, crystallizes on standing (m.p. 44 to 48° C.).
2,2,6,6-Tetramethyl-piperidine-4-[4-(trans-4-propylcyclohexyl)]benzoate was obtained in analogy to example 7 from 4-(trans-4-propylcyclohexyl)benzoyl chloride.
2,2,6,6-Tetramethyl-piperidine-4-[4-(5-hexyl-pyrimidin-2-yl)]benzoate was obtained in analogy to example 7 from 4-(5-hexyl-pyrimidin-2-yl)benzoylchloride.
2,2,6,6-Tetramethyl-piperidine-4-[4′-(4-decyloxy)benzoyloxy-biphenyl-4-yl]carboxylate was obtained in analogy to example 7 from [4′-(4-decyloxy)benzoyloxy-biphenyl-4-yl]carboxylic acid chloride.
2,6,6-Tetramethyl-piperidine-4-(4-hexyl)benzoate was obtained in analogy to RO 92779 B1 (CAN 109:171562) by heating a xylene solution of methyl 4-hexylbenzoate, 4-hydroxy-2,2,6,6-tetramethylpiperidine and sodium methanolate to reflux for 10 hrs. Silica treatment and recrystallization rendered pure material of m.p. 61-62° C.
2,2,6,6-Tetramethylpiperidine-4-(4′-heptylbiphenyl-4-yl)carboxylate was obtained in analogy to example 13 by subjecting methyl 4′-heptylbiphenyl-4-carboxylate to the reaction with 4-hydroxy-2,2,6,6-tetramethylpiperidine; m.p. 106-107° C.
1,2,2,6,6-Pentamethyl-4-[trans-4-(4-propylcyclohexyl)phenyl]piperidine was obtained in analogy to Skowronski et al., Pol. J. Chem. 54, 195, (1980) by reacting in tetrahydrofurane 1,2,2,6,6-pentamethyl-piperidine-4-one with the Grignard reagent prepared from 4-(trans-4-propylcyclohexyl)bromobenzene, subjecting the crude reaction product to azeotropic dehydration to 3,4-dehydro-1,2,2,6,6-pentamethyl-4-[trans-4-(4-propylcyclohexyl)phenyl]piperidine and hydrogenation in tetrahydrofuran, catalyzed by Pd/C, at ambient temperature and atmospheric pressure, followed by silica treatment, as a viscous liquid. 1H-NMR (300 MHz, CDCl3/DMSO/TMS) δ=7.18 m, 4H), 2.65-2.49 (m, 2H), 2.24 (s, 3H), 1.95-1.80 (m, 6H), 1.55-1.15 (m, 9H), 1.12-0.96 (m, 14H), 0.91 (t, 3H)
Table 2 summarizes the results—(achieved with the equipment and procedure of examples 1 to 6) obtained by adding small quantities of several types of (I) to one of the following Sc mixtures:
TABLE 2
Ion Content [nc/cm2]
storage
storage
storage
storage
storage
example
condition
mixture
0 hrs
100 hrs
200 hrs
300 hrs
500 hrs
reference.
20 V, 5 Hz
M1
<0.01
0.3
0.35
0.48
0.25
16
20 V, 5 Hz
M1 + 5%
<0.01
<0.01
<0.01
<0.01
<0.01
expl. 13
reference.
20 V, 5 Hz
M3b
0.21
4.69
4.36
4.37
4.32
17
20 V, 5 Hz
M3b + 0.1%
0.17
0.3
0.48
0.47
0.54
expl. 13
18
20 V, 5 Hz
M3b + 0.2%
0.08
0.23
0.23
0.25
0.27
expl. 13
19
20 V, 5 Hz
M3b + 0.4%
0.16
0.23
0.2
0.22
0.25
expl. 13
reference.
5 V, 0.1 Hz
M4
0
2.56
7.57
3.48
6.33
20
5 V, 0.1 Hz
M4 + 0.4%
<0.01
<0.01
0.12
0.22
0.17
expl. 13
reference.
5 V, 0.1 Hz
M2
0.2
8.18
10.93
9.49
6.43
21
5 V, 0.1 Hz
M2 + 0.4%
<0.01
<0.01
0.08
0.48
0.73
expl. 13
22
5 V, 0.1 Hz
M2 + 0.2%
<0.01
1.76
2.37
2.08
1.87
expl. 14
23
5 V, 0.1 Hz
M2 + 0.4%
<0.01
1.14
1.57
1.41
no data
expl. 14
24
5 V, 0.1 Hz
M4 + 0.2%
<0.01
1.91
2.71
2.79
2.94
expl. 14
25
5 V, 0.1 Hz
M4 + 0.4%
<0.01
2.02
2.80
3.09
2.91
expl. 14
As can be seen by comparing with the respective reference examples {comprising no (I)}, the mixtures according to invention surprisingly exhibit a substantially lower ion content [nC/cm2] over a longer period of time.
Schmidt, Wolfgang, Nonaka, Toshiaki, Hornung, Barbara, Wingen, Rainer, Li, Ji, Ogawa, Ayako, Dübal, Hans-Rolf
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 3663558, | |||
| 3847930, | |||
| 3937711, | Oct 15 1973 | Ciba-Geigy Corporation | 4-(Carboxamidoethyl) piperidines |
| 3939168, | Jul 28 1972 | Ciba-Geigy Corporation | 4-Piperidine acetamides |
| 4038280, | Nov 30 1971 | Ciba-Geigy Corporation | Hydroxyaryl-tetramethyl-piperidines |
| 4153596, | Sep 21 1976 | Bayer Aktiengesellschaft | Permanently stabilized polymers produced by after-treatment with piperidine compounds |
| 4537698, | May 28 1982 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Liquid crystalline piperidine derivatives |
| 5851682, | Feb 28 1994 | Sumitomo Chemical Company, Limited | Polyolefin resin composition and resin film |
| 6824707, | Oct 23 2001 | AZ ELECTRONIC MATERIALS GERMANY GMBH | Active matrix liquid crystal device and smectic liquid crystal mixture |
| 6958176, | Aug 30 2000 | Merck Patent GmbH | Liquid crystal mixture |
| 8349210, | Jun 27 2008 | Transitions Optical, Inc | Mesogenic stabilizers |
| GB849282, | |||
| JP11021325, | |||
| JP5523169, | |||
| JP58168641, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 11 2005 | Merck Patent GmbH | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Feb 16 2019 | 4 years fee payment window open |
| Aug 16 2019 | 6 months grace period start (w surcharge) |
| Feb 16 2020 | patent expiry (for year 4) |
| Feb 16 2022 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Feb 16 2023 | 8 years fee payment window open |
| Aug 16 2023 | 6 months grace period start (w surcharge) |
| Feb 16 2024 | patent expiry (for year 8) |
| Feb 16 2026 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Feb 16 2027 | 12 years fee payment window open |
| Aug 16 2027 | 6 months grace period start (w surcharge) |
| Feb 16 2028 | patent expiry (for year 12) |
| Feb 16 2030 | 2 years to revive unintentionally abandoned end. (for year 12) |